Corfogoto

A A F O B

AAFOBT e c h n o l o g y

BMMbiotecnologíamicrobiana marina

Universidad de Valparaíso Chile

TechTranfer Office

Marine natural product

Surface active molecules

Produced and obtained from a marine bacterium by a controled cost-effective bioprocess

Physical Food Industry

Biological Aquaculture 90 % 1,4 million pof tons

AAFOBT e c h n o l o g y

The only way to meet the increasing demand for fish is through aquaculture

Daniel Cressey, Nature 458, 398-400 (2009

Biomass increases and pathogen apparitions

Aquaculture challenges

Economic loses Food safety

Pathogen outbreaks

Green actions

Avoid antibioticsNew functional diets

AAFOBT e c h n o l o g y

+ +

USERS: SALMON FARMS CUSTOMER: FEED INDUSTRY

AAFOBT e c h n o l o g y

Fast growing economic activity 8,8 % of annual growth rate

60 million tonnes in 2010 with a value of U$ 119 billion

Mayor producer: China with 60 %

Mill

ion

tons

Billions people

Funcional Diets

QUORUM SENSING AND PATHOGENICITY

AAFOB

Chemical Signal for Quorum Sensing

VIRULENCEACTIVATED

VIRULENCEINHIBITED

Inhibitions by AAFOB is selective without resistence generation

Quorum sensing is involved in fish pathogens

AAFOBT e c h n o l o g y

ANTIBIOTICS VACCINES AAFOB

Specificity

Resistance

Production cost

Implementation cost

Food safety

Environment

X

X

X

X

X

X

COMPETITORS

AAFOBT e c h n o l o g y

CUSTOMER BENEFITS •BIOMASS PRODUCTION •FOOD SAFETY

Biosurfactant  Technology  

Physical  and  chemical  proper1es    •  Amphiphilic  compounds  

•  Reduc8on  of  surface  an  interfacial  tension  

•  Incorpora8on  on  different  matrices.      Biological  proper1es    •  Interference  with  cell-­‐to-­‐cell  communica8on  

system  :  Quorum  Sensing  

•  Inhibi8on  of  virulence  factors  expression  

•  Immunomodula8on  

Incorpora1on  of  BS  into  polymeric  matrices:      •  BIO-­‐Silicone    urinary  catheters  

   Advantages:    •  No  bacterial  resistance  

•  Large  scale-­‐produc8on  

•  Reduce  usage  of  potable  water  

Catheter-­‐associated  Urinary  Tract  Infec8ons  

•  27% of total health-care associated

infections.1

•  Catheterization increases the infection risk in a 5%, per day.2

•  Bac te r i a l s t ra i n s r e s i s t an t t o conventional antibiotic therapies.

•  Each CAUTI increase medical care

costs in U$600, per patient.3

•  Bacteremia caused by CAUTI increase medical care costs in U$2800, per patient.4

1  HELICS,  2005.    2  Garidaldi  RA,  Burke  JP,  Dickman  ML  and  Smith  CB  (1974).  Factors  predisposing  to  bacteriuria  during  indwelling  urethral  catheterisa8on.  The  New  England  Journal  of  Medicine  291:213-­‐219.    3  Jarvis  WR.  Selected  aspects  of  the  socioeconomic  impact  of  nosocomial  infec8ons:  morbidity,  mortality,  cost,  and  preven8on.  Infect  Control  Hosp  Epidemiol.  1996;17(8):552–7  4Tambyah  PA,  Knasinski  V,  Maki  DG.  The  direct  costs  of  nosocomial  catheter-­‐associated  urinary  tract  infec8on  in  the  era  of  managed  care.  Infect  Control  Hosp  Epidemiol.  2002;23(1):27–31  

AAFOBT e c h n o l o g y

AAFOB TECH TRANSFER

Scientific validation

and Patent

Chilean

International PCT

Fondef D07I1061

Corfo Innova L4

Licences Productive

Comercial

Corfo Innova L4

Trade Mark INAPI

Spin off Micro MBtk Biotk Corfo Innova L4

Fondef VIU

Investors seeking to implement production and distribution

UE and EEUU Corfo GoTo Market

OK

Developing

Funded by

AAFOBT e c h n o l o g y

Go To Market Barriers

Local Regulations

Production

Distribution

Natural products Toxicity assays (in vitro and LD50) Field assay with AAFOB based diets

HC Industrial Fermentation is required

For global market

AAFOBT e c h n o l o g y

AAFOBT e c h n o l o g y

Biomedicine

Aquaculture

Industry

Enregy

AAFOBT e c h n o l o g y

Marine natural products can support the sustainable growth of an aquaculture safe for people and environmentally friendly